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Abstract Solid tumors arising from malignant transfor-
mation of glial cells are one of the leading causes of central
nervous system tumor-related death in children. Recur-
rence in spite of rigorous surgical and chemoradiation
therapies remains a major hurdle in management of these
tumors. Here, we investigate the efficacy of the second-
generation receptor tyrosine kinase inhibitor nilotinib as a
therapeutic option for the management of pediatric glio-
mas. We have utilized two independent pediatric high-
grade glioma cell lines with either high platelet-derived
growth factor receptor alpha (PDGFRa) or high PDGFRb
expression in in vitro assays to investigate the specific
downstream effects of nilotinib treatment. Using in vitro
cell-based assays we show that nilotinib inhibits PDGF-
BB-dependent activation of PDGFRa. We further show
that nilotinib is able to decrease cell proliferation and an-
chorage-independent growth via suppression of AKT and
ERK1/2 signaling pathways. Our results suggest that
nilotinib may be effective for management of a PDGFRa-
dependent group of pediatric gliomas.
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Introduction
Malignant glial neoplasms comprise 8–10 % of primary
pediatric central nervous system (CNS) tumors [1], and
are the most common cause of solid tumor-related death
in children [2]. These lesions are classified as grade III or
IV by the World Health Organization (WHO), and his-
tology is most commonly anaplastic astrocytoma (AA;
grade III) and glioblastoma (GBM; grade IV) [3]. The
cornerstones of therapy remain surgical resection and
adjuvant chemoradiation, but tumor recurrence is inevi-
table and long-term response to treatment remains ex-
tremely poor. Development of novel therapies has been
restricted by limited understanding of tumor biology and
dependence upon preclinical models based on adult
disease.
Genomic studies of pediatric high-grade gliomas (HGG)
have demonstrated that the most frequent copy number
aberration (CNA) is focal amplification of the platelet-
derived growth factor receptor (PDGFRA) locus at chro-
mosome 4q12, encoding the a isoform of platelet-derived
growth factor receptor (PDGFRa) [4–7]. Several exome
sequencing profiles of high-grade pediatric supratentorial
and brainstem gliomas revealed a frequent, novel mutation
of H3F3A, encoding histone variant H3.3, that is associated
with poorer overall survival [8, 9]; among brainstem le-
sions, amplification of PDGFRA occurred exclusively in
H3F3A-mutant tumors [10]. PDGFRa protein expression
corresponds to gene amplification, and is also seen in some
tumors that do not contain PDGFRA amplification [11].
Expression of PDGFR correlates with high-grade histology
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in pediatric gliomas [12], and associated activation of
downstream Ras- and AKT-pathway signaling mediators
has been correlated with poor survival [13, 14].
The second-generation receptor tyrosine kinase inhibitor
nilotinib (Tasigna; Novartis Pharmaceuticals) binds its
targets with similar affinity to the prototype molecule
imatinib (Gleevec; Novartis Pharmaceuticals) [15–19].
Unlike imatinib, it is not dependent upon the OCT-1
transporter for cell influx [20], and although it may be
subject to transporter-dependent efflux [21, 22], it is de-
tectable within the brains of mice with an intact blood–
brain barrier [23]. Currently in use for treating imatinib-
resistant and newly diagnosed chronic myeloid leukemia,
nilotinib has a well-established safety and toxicity profile
[24, 25]. In this study, we examine the effects of nilotinib
on pediatric GBM-derived cell lines, in order to understand
the biochemical and biological impact of inhibiting
PDGFR signaling and to evaluate its suitability as a
therapeutic target.
Materials and methods
Cell lines and culture
Pediatric GBM cell lines SJ-G2 and SF-188 [26, 27] were a
gift from Dr. Nada Jabado (McGill University, Montreal,
Quebec), and normal human astrocytes (NHA) immortal-
ized with E7 and hTERT were a gift from Dr. Russell
Pieper (University of California, San Francisco, CA, USA).
Adult GBM cell lines U-118, U-87 and U-251 were ob-
tained from the American Type Culture Collection
(ATCC). All cell lines were cultured as adherent mono-
layers in minimal media supplemented with 10 % fetal
bovine serum (FBS), at 37 C in 5 % CO2.
Evaluation of exogenous ligand stimulation
and inhibition
Methods and results are presented below for SJ-G2; par-
allel experiments carried out in SF-188 are presented in
supplementary sections (see detailed methods in Supple-
ment). Culture stimulation was performed using dimerized
B-isoform of recombinant human platelet-derived growth
factor (PDGF-BB; Cell Signaling Technology), which has
affinity for both a and b isoforms of PDGFR. Cell cultures
at 70–80 % confluence were incubated overnight in growth
media containing 0.5 % FBS, then washed with warm
phosphate-buffered saline (PBS), and exposed to fresh
minimal media containing PDGF-BB at working concen-
tration. Stimulation was terminated by placing cultures on
ice and washing with cold PBS, then scraping and sus-
pending in cell lysis buffer.
Western immunoblot assay
Cell cultures were scraped and lysed on ice in 1X Cell
Lysis Buffer (Cell Signaling) containing protease (Roche
Diagnostics) and phosphatase inhibitors (Calbiochem).
Protein was quantified using bicinchoninic acid (BCA)
assay (Thermo Scientific), and lysate containing 25–40 lg
protein was loaded onto 7–12.5 % SDS-PAGE gels for
electrophoresis. A detailed list of antibodies used is pre-
sented in Supplementary methods.
Cell viability, proliferation and colony formation assays
Cell viability was assessed by MTS assay using CellTiter
96 Aqueous One Solution reagent (Promega) according to
the manufacturer’s instructions. Direct count of viable cells
using the trypan blue dye exclusion method was performed
with the Vi-CELL Cell Viability Analyzer (Beckman
Coulter). For cell proliferation assay, chemiluminescent
Cell Proliferation ELISA (Roche) using 5-bromo-20-deox-
yuridine (BrdU) labeling was carried out according to the
manufacturer’s instructions, using a 12-h labeling period.
Clonogenic assay and soft-agar colony-forming assay were
performed to evaluate in vitro growth potential [28].
Colonies were fixed in 10 % formalin, then stained with
0.05 % crystal violet. Each condition was carried out in
triplicate, in three independent experiments. Detailed
methods are described in Supplementary methods.
Subcutaneous xenograft
SJ-G2 cells (1 9 106) were injected into the right flank of
6–8-week-old NOD–SCID mice (Jackson Laboratory). On
detection of palpable tumor, mice were given nilotinib or
vehicle by oral gavage (10 mg/kg daily), and sacrificed upon
signs of sickness or at the end of the 10-week study. Excised
tumor dimensions were measured with calipers, and volume
estimated by the formula 4pabc/3, where a, b and c represent
tumor radius in three planes. Animal use protocols were
approved by the animal care committed of the Hospital for
Sick Children (Toronto, Canada) under AUP#2656.
Results
PDGFR protein expression in pediatric GBM cell lines
To assess relative expression levels of PDGFR proteins, the
pediatric GBM cell lines SJ-G2 and SF-188 were compared
to adult GBM cell lines and to non-transformed human as-
trocytes using immunoblotting. We found that NHA ex-
pressed PDGFRb but not PDGFRa. SF-188 followed this
pattern, by expressing minimal PDGFRb and not PDGFRa.
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In contrast, SJ-G2 contained large amounts of PDGFRa, and
far less PDGFRb (Fig. 1a). Results for SJ-G2 are presented
throughout, and parallel experiments carried out in SF-188
are presented in Supplementary Data and Figures. Neither
pediatric GBM cell line was found to contain high-level
amplification of PDGFRA (Supplementary Fig. 1S). In
summary, pediatric GBM—like adult GBM—contains
variable expression of the two PDGF receptors.
Activation of PDGFRa is PDGF-BB-dependent
When grown in low-serum conditions, SJ-G2 cells contained
minimal phosphorylated PDGFRa. Addition of exogenous
PDGF-BB to growth media resulted in phosphorylation of
PDGFRa. Phosphorylation increased with increasing ligand
concentration to a plateau C50 ng/mL (Fig. 1b). Based on
this finding, to ensure maximal phosphorylation, we carried
out subsequent stimulation using PDGF-BB at a concentra-
tion of 80 ng/mL. The largest fraction of phosphorylated
receptor was seen following one minute of stimulation, the
earliest time point measured (Fig. 1c). As exposure time to
ligand was lengthened, the amount of phosphorylated
receptor and total receptor decreased. In order to ensure re-
producibility during subsequent stimulation, we chose a
stimulation duration of 5 min.
PDGFRa stimulation and downstream signaling is
inhibited by nilotinib
We observed a dose-dependent effect on number of viable
cells in culture between 0 and 3 lMnilotinib (see below), so
chose an overlapping concentration range to examine sig-
naling effects. To evaluate the effect of PDGFR activation on
the downstream AKT and Ras pathways, we monitored
phosphorylation of AKT S473 and ERK1/2 T202/Y204 in
the presence and absence of nilotinib. In low-serum growth
conditions, background phosphorylation of PDGFRa was
minimal, and activation of AKT and ERK1/2 was not de-
tected (Fig. 2a). Exposure to exogenous PDGF-BB resulted
in increased phosphorylation of PDGFRa, as well as AKT
and ERK1/2. The presence of 3 or 5 lM nilotinib during
PDGF-BB stimulation resulted in little PDGFRa activation,
and the phosphorylation of AKT and ERK1/2 were also
significantly reduced. The activation of PDGFRa was
evaluated using an antibody specific to phospho-tyrosine
754, but immunoblotting with a pan-phosphotyrosine anti-
body also demonstrated that phosphorylation of tyrosine
residues at the molecular weight of PDGFR was generally
reduced in the presence of nilotinib (Fig. 2b).
Nilotinib inhibition of PDGFRa in serum decreases
activation of AKT and ERK1/2 signaling
We then evaluated the effects of niloinib inhibition in the
more complex milieu of serum-supplemented growth me-
dia, and additionally examined the phosphorylation of S6
ribosomal protein, which effects enhanced mRNA trans-
lation in AKT-stimulated cell growth, and of MEK, a direct
activator of ERK1/2. In serum-supplemented growth me-
dia, a low basal level of PDGFRa phosphorylation was
observed (Fig. 3, row 1 of graphs). Basal activation of
AKT, S6 ribosomal protein, MEK and ERK1/2 was ob-
served. To evaluate the effect of nilotinib on activation of
PDGFRa and its signaling pathways, each inhibition con-
dition was compared to this basal phosphorylation. Cul-
tures were first exposed to 0–10 lM nilotinib for 2 h
(Fig. 3, first column of graphs). With increasing nilotinib
concentration, phosphorylation of PDGFRa was sig-
nificantly decreased. During this time period, a small de-
crease in AKT activation was noted, as well as a marked
decrease in S6 ribosomal protein phosphorylation. (Fig. 3,
rows 2 and 3 of graphs). When exposure to 3 lM nilotinib
was then extended to 6 and 24 h (Fig. 3, second column of
graphs), a further reduction in AKT activation was seen,
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Fig. 1 Expression and activation of PDGFRa. a Variable expression
of PDGFRa and b is demonstrated in pediatric (SF-188, SJ-G2) and
adult (U-87, U-251, U-118) glioblastoma cell-lines. b Western blot
analysis of PDGFRa phosphorylation following exposure to exoge-
nous PDGF-BB under varying conditions. Vinculin is loading control.
SJ-G2 cells were exposed to 0–100 ng/mL PDGF-BB for 5 min. A
concentration-dependent increase in PDGFRa phosphorylation was
observed, to a plateau C50 ng/mL. c SJ-G2 cells were exposed to
100 ng/mL PDGF-BB for 0–60 min. Phosphorylation of PDGFRa
occurred rapidly, with a peak observed following 1 min of ligand
exposure
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was sustained. Initial exposure to nilotinib resulted in
stimulation of MEK activation (Fig. 3, row 4 of graphs).
As exposure to 3 lM nilotinib was prolonged, however,
MEK phosphorylation decreased, and after 24 h, was
suppressed below baseline. ERK1/2 activation was not
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Fig. 2 Nilotinib inhibits PDGF-BB-dependent activation of
PDGFRa. SJ-G2 cultures in low-serum growth conditions were
stimulated with exogenous PDGF-BB in the absence and presence of
nilotinib. Accompanying bar graphs display relative phosphorylation
in each condition, compared with stimulation in 0 lM nilotinib
treatment (maximal stimulation). Significant difference is indicated
by * for p\ 0.05, ** for p\ 0.01, and *** for p\ 0.001. a Western
blot analysis of PDGFRa, AKT and ERK1/2 phosphorylation. b-actin
is loading control. Minimal basal phosphorylation of PDGFRa was
observed, and little activation of downstream signaling mediators.
Exposure to PDGF-BB resulted in phosphorylation of PDGFRa and
activation of AKT and ERK1/2. Treatment with nilotinib decreased
PDGFRa phosphorylation and the associated activation of down-
stream signaling mediators. b Immunoblotting of total cell lysate
detected global reduction of phospho-tyrosine at the molecular weight
of PDGFRa in the presence of nilotinib. Vinculin is loading control
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treatment, but decreased following 24 h of exposure
(Fig. 3, row 5 of graphs).
Nilotinib decreases SJ-G2 proliferation
A dose-dependent effect on cell viability was demonstrated
by MTS assay when SJ-G2 cells were treated with nilotinib
(0–10 lM) (Fig. 4a). Following C1 day of exposure to the
inhibitor, the viability of all treated cultures was less than
that of vehicle-treated control. After C2 days of exposure,
fewer viable cells were seen in cultures exposed to C3 lM
nilotinib compared to cultures in 1 lM nilotinib. There was
no consistent difference in effect on viable cell numbers
between 3 and 10 lM nilotinib. To determine whether the
effect on viability was sustained, SJ-G2 was cultured in the
presence of nilotinib (0–10 lM) up to 14 days (Fig. 4b).
Number of viable cells in treated cultures was significantly
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Fig. 3 Nilotinib inhibits PDGFRa and the AKT and ERK1/2
signaling pathways. SJ-G2 cultures in 10 % FBS-supplemented
growth media were exposed to nilotinib 0–10 lM for 2 h, and to
3 lM for up to 24 h. Phosphorylation of PDGFRa, AKT, S6
ribosomal protein, MEK and ERK1/2 was analyzed by Western
blotting. b-actin is loading control. Accompanying bar graphs display
relative phosphorylation in each condition, compared with basal
levels (0 lM nilotinib vehicle treatment). Significant difference is
indicated by * for p\ 0.05, ** for p\ 0.01, and *** for p\ 0.001.
Basal phosphorylation of all proteins was demonstrated. Exposure to
nilotinib resulted in reduction of PDGFRa phosphorylation. Phos-
phorylation of AKT and S6 ribosomal protein was also decreased, and
continually suppressed with extended inhibitor treatment. Phospho-
rylation of MEK was initially increased, but sustained exposure to
nilotinib resulted in suppression below baseline. ERK1/2 activation
was decreased following 24 h of nilotinib treatment
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4 days of inhibition and continued through 14 days of
exposure. This result was corroborated using direct
counting of viable cells using trypan blue dye exclusion;
when treated for 4 or more days, all SJ-G2 cultures exposed
to C3 lM nilotinib contained significantly fewer viable
cells compared to vehicle-treated control (Fig. 4c). There
was no consistent difference among the cultures treated
with 3–10 lM nilotinib. Apoptosis assays were also
performed but no significant differences were noted (data
not shown).
To evaluate the effect of nilotinib on SJ-G2 prolif-
eration, we assessed the incorporation of BrdU by chemi-
luminescent ELISA (Fig. 4d). Following 2 and 4 days of
exposure, all treated cultures (3–10 lM) generated sig-
nificantly less luminescent product than vehicle-treated
control.







































































































Day 1 Day 2 Day 3 Day 4
0µM vs 1µM * *** *** ***
0µM vs 3µM *** *** *** ***
0µM vs 5µM *** *** *** ***
0µM vs 10µM *** *** *** ***
1µM vs 3µM ns ** *** ***
1µM vs 5µM ns *** *** ***
1µM vs 10µM ns *** *** ***
3µM vs 5µM ns ns ns ns
3µM vs 10µM ns ns ns ns

















Fig. 4 Nilotinib reduces SJ-G2 growth and proliferation. Cell cultures
treated with nilotinib were compared with vehicle-treated controls.
Significant difference is indicated by * for p\ 0.05, ** for p\ 0.01,
and *** for p\ 0.001. a SJ-G2 cultures were exposed to nilotinib
(0–10 lM) for 1–4 days. MTS assay demonstrated a dose-dependent
effect on numbers of viable cells in culture. All treated cultures
demonstrated significantly fewer viable cells compared to control, and a
further difference was seen between 1 lM and C3 lM nilotinib
treatment. b Durability of effect on cell numbers was evaluated by
exposing SJ-G2 cultures to nilotinib (0–10 lM) for 2–14 days. Treated
cultures exhibited fewer viable cells up to 14 days. c SJ-G2 cultures
were exposed to nilotinib (0–10 lM) for 2–6 days. The number of
viable cells, as determined by exclusion of trypan blue dye, was lower in
the presence of nilotinib. d SJ-G2 cultures were exposed to nilotinib
(0–10 lM) for 2–4 days. Incorporation of BrdU as detected by ELISA
was decreased in treated cultures
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Nilotinib decreases in vitro and in vivo tumorigenicity
The number of colonies formed in clonogenic assay was
decreased in the presence of all concentrations of nilotinib
(Fig. 5a). Anchorage-independent growth of SJ-G2 cells
suspended in soft agar was also significantly decreased by
exposure to nilotinib (Fig. 5b). Mice harboring SJ-G2
xenograft tumors survived significantly longer (p = 0.0006)
when treated with nilotinib, compared with mice given drug
vehicle (Fig. 5c). Tumors excised from treated mice were
smaller at the time of animal sacrifice (Fig. 5d). Two treated
animals did not become ill; at the end of the study period, the
subcutaneous masses that had been identified were found to
be fibrofatty tissue.
Discussion
Demonstration of PDGFRA amplification as the most
common CNA among pediatric HGG, and the association
of histone H3.3 mutation in malignant pediatric brain-stem
glioma with PDGFRA amplification, identified PDGFRa
and its signaling pathways as likely integral to the malig-
nant behavior of some tumors. It is therefore identified as a
potential therapeutic target. Recognizing that understand-
ing of this disease and advancement of therapy has his-
torically been hindered by reliance upon studies of adult
gliomas, we have carried out investigations of PDGFRa
signaling and inhibition in cell lines derived from pediatric
glioblastoma tumors.
Pediatric high-grade tumors exhibit variability in
PDGFRA copy number, as well as in expression of PDGFRa
and in platelet-derived growth factor (PDGF) itself [11, 29–
31]. Although the SJ-G2 cell line does not contain amplifi-
cation ofPDGFRA, its expression of high levels of PDGFRa,
the activation of which is dependent on dosage of ligand
(PDGF-BB), suggests that it represents tumors that use
PDGFRa signaling to support their tumorigenic behavior. To
our knowledge, this is the first demonstration in a pediatric
GBM cell line that activation of PDGFR is dependent upon
ligand binding. This stands in contrast, for instance, to con-























































































Fig. 5 Nilotinib reduces SJ-G2 in vitro and in vivo growth. a Plate-
attached SJ-G2 cells were exposed to nilotinib (0–10 lM) for
21 days. Colony numbers in the presence of nilotinib were compared
to vehicle-treated controls; significant difference is indicated by **
for p\ 0.01 and *** for p\ 0.001. b SJ-G2 cells suspended in
0.35 % agar were exposed to nilotinib (0–10 lM) for 21 days.
Colony numbers in the presence of nilotinib were compared to
vehicle-treated controls; significant difference is indicated by *** for
p\ 0.001. c Kaplan–Meier plot for NOD–SCID mice bearing SJ-G2
flank tumors. Animals treated with nilotinib demonstrated prolonged
survival. d Excised xenograft tumors that had been exposed to
nilotinib were smaller than those from vehicle-treated mice. Sig-
nificant difference is indicated by * for p\ 0.05
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factor receptor that are frequently found in adult GBM [32,
33]. Activation of PDGFRa occurred rapidly, with peak
phosphorylation seen within a minute of exposure to PDGF-
BB, and decayed, suggesting that normal mechanisms of
receptor internalization and degradation remain functional in
these cells [34].
Ligand-mediated PDGFR stimulation activates the
PI3K–AKT and Raf–MEK–ERK signaling pathways [35–
37] and is dependent upon cell type and developmental
stage [38–40]. Stimulation with PDGF-BB of SJ-G2 cells
resulted in phosphorylation of PDGFRa and corresponding
activation of AKT and ERK1/2. Exposure to nilotinib in-
hibited PDGF-BB-mediated stimulation of the receptor,
and markedly decreased activation of AKT and ERK1/2.
Phosphorylation of tyrosine in response to PDGF-BB was
generally decreased in the presence of nilotinib, suggesting
that PDGFRa auto-activation was inhibited.
The effect of nilotinib inhibition was subsequently ex-
amined in the heterogeneous environment of serum-sup-
plemented growth media. In this setting, we observed a low
basal level of PDGFRa phosphorylation. Consistent with
ongoing PDGFRa stimulation, we also detected basal acti-
vation of AKT, S6 ribosomal protein, MEK and ERK1/2,
although activation of other cell-surface receptors may have
contributed to this. Exposure to nilotinib decreased PDGFRa
phosphorylation in all conditions. Phosphorylation of AKT
and S6 ribosomal protein was rapidly reduced, and was
maintained at a significantly decreased level during sus-
tained inhibitor exposure, suggesting that some component
of their activation is PDGFR-dependent. Interestingly, there
was an early increase in MEK phosphorylation, within the
first 2 h of nilotinib exposure. The rapidity of this change
suggests that it results from an alteration in steady-state
balance between signaling pathways.
Since inhibition with nilotinib suppressed PDGFRa-me-
diated signaling, we then investigated its effect on SJ-G2 cell
numbers and proliferation. Our results show that cell prolif-
eration and clonogenic potential (in vitro tumor-forming
ability) were significantly reduced at 3 lM nilotinib com-
pared to vehicle-treated control. The reduced proliferation
resulted in fewer viable cells over the same time interval of
growth compared to untreated controls. As patients receiving
typical oral dosaging of nilotinib achieve a mean peak serum
concentration of 3.6 lM [24], the plateau in effect suggests
that maximal anti-PDGFRa effect occurs at a concentration
that can be achieved safely in the clinical context. The in vitro
results were supported by in vivo findings of prolonged sur-
vival in nilotinib-treated mice bearing SJ-G2 tumors, and
smaller tumor sizes in the treated mice.
These functional assays indicate that the result of nilo-
tinib-mediated decrease in PDGFRa activation and sig-
naling is a reduction in SJ-G2 proliferation, colony
formation and in vivo growth. This overall decrease in
tumorigenic behavior suggests that SJ-G2 may represent
tumors that depend upon PDGFRa signaling and would
therefore respond to nilotinib inhibition.
In contrast, SF-188 expressed very little PDGFRa and
demonstrated high basal activation of AKT and ERK1/2,
suggesting that this cell line is dependent upon activation of
alternative growth factor receptor pathways to transduce
mitogenic signals (Supplementary Figs. 2S, 3S, 4S). Con-
sistent with this, we found that treatment with nilotinib had
little effect on activation of AKT and ERK1/2. Furthermore,
while treated cultures of SF-188 initially demonstrated lower
viability, this difference was lost with sustained inhibition.
SF-188 contains amutation of the tumor suppressor and Ras-
GAP NF1 [41], which likely maintains activation of both
AKT and ERK1/2 pathways by failing to regulate Ras acti-
vation. In contrast to SJ-G2, which contains wildtype NF1,
SF-188 can be seen to represent the subset of tumors that do
not depend upon PDGFRa activation.
All chemotherapeutic agents intended for use in the
CNS must be able to penetrate the blood–brain barrier.
Although its predecessor imatinib has poor CSF penetra-
tion [42], regarding this question nilotinib remains under
clinical investigation. Interestingly, nilotinib demonstrates
in vivo activity against Abelson tyrosine kinase (Abl)
within neurons of murine basal ganglia [23].
As our understanding of the biology of pediatric HGG
evolves, so does our recognition that they are a clinical and
pathological entity distinct from adult tumors—and, indeed,
that they encompass different subtypes. In this study, we
identified the SJ-G2 cell line as representative of tumors that
are dependent upon PDGFRa expression and activation to
drive signaling pathways leading to tumorigenic behavior,
and which are therefore most likely to be responsive to in-
hibition with nilotinib. Based on these data, we suggest that a
subset of appropriately-identified pediatric HGG should be
considered candidates for nilotinib treatment.
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